135 related articles for article (PubMed ID: 22752886)
1. Mortality in Barrett's esophagus: three decades of experience at a single center.
Caygill CP; Royston C; Charlett A; Wall CM; Gatenby PA; Ramus JR; Watson A; Winslet M; Bardhan KD
Endoscopy; 2012 Oct; 44(10):892-8. PubMed ID: 22752886
[TBL] [Abstract][Full Text] [Related]
2. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
3. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.
Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D
Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444
[TBL] [Abstract][Full Text] [Related]
4. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma].
Incarbone R; Bonavina L; Bassi F; Peracchia A
Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454
[TBL] [Abstract][Full Text] [Related]
5. Barrett's esophagus-is it bad for your health?
Falk GW
Am J Gastroenterol; 2005 Dec; 100(12):2622-3. PubMed ID: 16393210
[TBL] [Abstract][Full Text] [Related]
6. Risk of mortality and cancer incidence in Barrett's esophagus.
Cook MB; Wild CP; Everett SM; Hardie LJ; Bani-Hani KE; Martin IG; Forman D
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2090-6. PubMed ID: 17890521
[TBL] [Abstract][Full Text] [Related]
7. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study.
Solaymani-Dodaran M; Logan RF; West J; Card T
Am J Gastroenterol; 2005 Dec; 100(12):2616-21. PubMed ID: 16393209
[TBL] [Abstract][Full Text] [Related]
8. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
9. Cause-specific mortality of people with Barrett's esophagus compared with the general population: a population-based cohort study.
Solaymani-Dodaran M; Card TR; West J
Gastroenterology; 2013 Jun; 144(7):1375-83, 1383.e1. PubMed ID: 23583429
[TBL] [Abstract][Full Text] [Related]
10. Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus.
Schouten LJ; Steevens J; Huysentruyt CJ; Coffeng CE; Keulemans YC; van Leeuwen FE; Driessen AL; van den Brandt PA
Clin Gastroenterol Hepatol; 2011 Sep; 9(9):754-61. PubMed ID: 21570484
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
12. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus.
Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A
Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675
[TBL] [Abstract][Full Text] [Related]
13. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.
Conio M; Blanchi S; Lapertosa G; Ferraris R; Sablich R; Marchi S; D'Onofrio V; Lacchin T; Iaquinto G; Missale G; Ravelli P; Cestari R; Benedetti G; Macrì G; Fiocca R; Munizzi F; Filiberti R
Am J Gastroenterol; 2003 Sep; 98(9):1931-9. PubMed ID: 14499768
[TBL] [Abstract][Full Text] [Related]
14. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
[TBL] [Abstract][Full Text] [Related]
15. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus.
Cameron AJ; Ott BJ; Payne WS
N Engl J Med; 1985 Oct; 313(14):857-9. PubMed ID: 4033716
[TBL] [Abstract][Full Text] [Related]
16. Incidence of adenocarcinoma among patients with Barrett's esophagus.
Hvid-Jensen F; Pedersen L; Drewes AM; Sørensen HT; Funch-Jensen P
N Engl J Med; 2011 Oct; 365(15):1375-83. PubMed ID: 21995385
[TBL] [Abstract][Full Text] [Related]
17. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
[TBL] [Abstract][Full Text] [Related]
18. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
[TBL] [Abstract][Full Text] [Related]
19. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
20. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
